Rentosertib is the first drug candidate whose target was found by software and whose molecule was designed by software. Six ageing clocks, built by four different groups, were pointed at the trial's blood samples. All six said the treated patients had got biologically younger.

The analysis, published in Nature Biotechnology on 7 September, used twelve weeks of proteomic data from 42 patients in a randomised, double blind, placebo controlled Phase IIa trial of rentosertib for idiopathic pulmonary fibrosis, run in China across 2023 and 2024. Six clock models built separately at Harvard, Oxford, Peking University and Insilico, among them ProtAge, OrganAge and PAC, each predicted a lower biological age in the treated arm. Forced vital capacity, the standard measure of lung function, improved in a dose dependent way alongside it. The drug inhibits TNIK, a target Insilico's PandaOmics platform identified as involved in six hallmarks of ageing, and the molecule came out of its Chemistry42 generative chemistry system.

Why this one is different

AI designed molecules have reached trials before. Both halves being machine chosen is newer, and having the result checked against models nobody at the company built is newer still. It is also the first head to head clinical comparison of several proteomic ageing clocks on one drug intervention, which makes it a test of the clocks as much as of the drug.

Six clocks, built by four groups, pointing the same way.

How we got here

1. 2020AlphaFold solves protein structure prediction at CASP, and computational biology stops being a supporting discipline.
2. 2024The Nobel Prize in Chemistry goes to work on protein structure and design.
3. 2023 to 2024The rentosertib Phase IIa trial runs in China, for lung fibrosis rather than for ageing.
4. 4 Sep 2026A model writes the first machine checked proof of Fermat's Last Theorem, 13 million lines in eleven days.
5. 7 Sep 2026Six independent ageing clocks agree about a drug whose target and molecule were both machine chosen.

What it does and does not mean

Predicted biological age is not biological age. A proteomic clock is a model that maps blood proteins to an estimated age, so six clocks agreeing is six estimates agreeing, not six measurements. Forty two patients is a small trial, Phase IIa is early, and the ageing finding is a secondary analysis of a study that was designed to treat lung fibrosis. Nobody has shown that moving a clock moves a life. What it does show is narrower and still worth having: a molecule whose target and structure were both chosen by software produced a measurable, dose consistent physiological effect in a controlled trial, the lung function result moved with the clocks rather than against them, and the drug is now in Phase III.